AIM ImmunoTech (AIM) - Long-Term Debt to Capital
AIM ImmunoTech (AIM) minimizes capital expenditures by outsourcing drug manufacturing and testing to third-party contractors. This daily price chart illustrates the 0.01 metric. The business relies on the exclusive ownership of Ampligen, utilizing RNA technologies to combat oncology and viruses. The firm is currently focusing on its own research, limiting external interaction solely to alliances with oncology centers.
AIM (AIM ImmunoTech Inc.): analytical breakdowns and indicator data
- price and consensus price forecast:
- market capitalization data:
- book capitalization data:
- debt and liquidity data:
Fundamental valuation:aimimmuno.com
For AIM ImmunoTech, which is pursuing costly biomedical developments, the ratio of long-term debt to equity serves as an indicator of financial autonomy. This metric compares liabilities with a maturity of more than one year against the amount of shareholder equity. This allows for an assessment of the company's dependence on debt financing in the absence of operating profit. A low leverage level is critically important for startups that rely on external investments. A high ratio signals bankruptcy risks should there be a delay in scientific results.
Competing companies
Long-Term Debt to Capital Coefficient argenx N.V.|Long-Term Debt to Capital BNTX|Long-Term Debt to Capital ABVX (Abivax S.A.)|Long-Term Debt to Equity ADMA Biologics|protagonist-inc.com - Long-Term Debt to Capital Coefficient|IMVT: Long-Term Debt to Equity|KNSA - Long-Term Debt to Equity Ratio|GRFS: Long-Term Debt to Capital|Long-Term Debt to Capital Adaptive Biotechnologies Inc.|CLDX - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient auriniapharma.com|BCRX (BioCryst Pharmaceuticals) - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital VERA (Vera Therapeutics Inc)|Dianthus Pharma - Long-Term Debt to Equity|Pharvaris Pharma - Long-Term Debt to Equity Ratio|ABCL: Long-Term Debt to Equity|tourmalinebio.com (TRML) - Long-Term Debt to Equity Ratio|PGEN: Long-Term Debt to Equity Ratio|PHAR (Pharming Group NV) - Long-Term Debt to Capital|Long-Term Debt to Equity Nektar (NKTR)|Long-Term Debt to Capital Ratio Upstream Pharma|Zenas Biopharma Inc - Long-Term Debt to Capital|Long-Term Liabilities to Capital immunome.com (IMNM)|Long-Term Debt to Capital GOSS (Gossamer Bio)|Long-Term Debt to Capital KalVista Pharma KALV|Long-Term Debt to Capital SEPN (Septerna Corp)|PVLA: Ratio of Long-Term Indebtedness to Capital|SVRA (Savara Inc.) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio rigel.com|ANAB - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient Astria Therapeutics Inc|ENGN (enGene Bio) - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital RAPT (rapt.com)|Aerovate Therapeutics - Long-Term Debt to Equity|aclaristx.com - Long-Term Debt to Equity Ratio|KYTX: Long-Term Debt to Equity|Tiziana Life Sciences Ltd. (TLSA) - Long-Term Debt to Equity Ratio|CABA: Long-Term Debt to Equity Ratio|VTYX (Ventyx Biosciences, Inc) - Long-Term Debt to Capital|Long-Term Debt to Equity Theratechnologies Inc. (THTX)|Long-Term Debt to Capital Ratio AVTX|Eledon Pharmaceuticals, Inc. - Long-Term Debt to Equity|Long-Term Liabilities to Capital Agenus, Inc. AGEN|Long-Term Debt to Equity Ratio Climb Bio, Inc. (CLYM)|Long-Term Loans to Capital Ratio zurabio.com ZURA|ATYR (aTyr Pharma, Inc.) - Long-Term Debt to Capital|ADAG - Long-Term Liabilities to Capital|IMA (ikenaoncology.com) - Long-Term Debt to Capital|Shattuck Labs (STTK) - Long-Term Debt to Equity Ratio|EQ - Long-Term Debt to Capital|Long-Term Debt to Capital Coefficient Connect Pharma|Long-Term Debt to Capital IMUX|Long-Term Debt to Capital atarabio.com (ATRA)|Long-Term Debt to Capital IFRX|X4 Pharmaceuticals Inc. - Ratio of Long-Term Indebtedness to Capital|ACET: Long-Term Debt to Equity|CELU: Long-Term Debt to Equity Ratio|Long-Term Debt to Equity INmune Bio, Inc. (INMB)|barinthusbio.com (BRNS) - Long-Term Liabilities to Equity|KZR - Long-Term Debt to Capital|Long-Term Debt to Capital Coefficient SAB Biotherapeutics Inc.|Long-Term Debt to Capital AKTX|Long-Term Debt to Capital ENLV (enlivex.com)|Long-Term Debt to Equity Q32 Bio|geovax.com - Long-Term Debt to Capital Coefficient|EDSA: Long-Term Debt to Equity|IBIO - Long-Term Debt to Equity Ratio|CARM: Long-Term Debt to Capital|Long-Term Debt to Capital XTL Bio|BOLT - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient HCW Biologics Inc|APVO (Aptevo Therapeutics) - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital ADTX (aditxt.com)|GRI Bio Corp - Long-Term Debt to Equity|XORTX Corp - Long-Term Debt to Equity Ratio|HIND: Long-Term Debt to Equity|revbiosciences.com (REVB) - Long-Term Debt to Equity Ratio|INDP: Long-Term Debt to Equity Ratio|SCNI (Scinai Immunotherapeutics Ltd) - Long-Term Debt to Capital|Long-Term Debt to Equity CalciMedica Inc (CALI)|Long-Term Debt to Capital Ratio Affimed Therapeutics|Allakos Inc. - Long-Term Debt to Capital|Long-Term Liabilities to Capital hookipapharma.com (HOOK)|Long-Term Debt to Capital IGMS (IGM Biosciences)|Long-Term Debt to Capital iTeos Therapeutics Inc ITOS|Long-Term Debt to Capital OCEA (Ocean Bio)|TCBP: Ratio of Long-Term Indebtedness to Capital|THRD (Third Harmonic Bio) - Long-Term Debt to Equity